ÐÓ°ÉÔ­´´

Tubulis has notable potential in developing chemotherapeutic drugs targeting cancer and chronic diseases. Based in Munich, the company focuses on innovative drug development to address limitations of existing chemotherapy treatments. Using a B2B model, Tubulis partners with larger pharmaceutical companies and healthcare providers, channeling their technological advancements into the market. Supported by investors such as Nextech Invest and EQT Life Sciences, Tubulis enjoys robust financial backing and industry credibility. Their specialized approach aims to offer more effective and targeted treatments, positioning them competitively against traditional chemotherapy options and potentially accelerating progress in combating serious health conditions.